References:
1. Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W,
Xiao G. Remdesivir and chloroquine effectively inhibit the recently
emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30:
269-71.
2. Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier
B, Courjon J, Giordanengo V, Vieira VE, Tissot Dupont H, Honore S,
Colson P, Chabriere E, La Scola B, Rolain JM, Brouqui P, Raoult D.
Hydroxychloroquine and azithromycin as a treatment of COVID-19: results
of an open-label non-randomized clinical trial. Int J Antimicrob Agents
2020; 56: 105949.
3. Niburski K, Niburski O. Impact of Trump’s Promotion of Unproven
COVID-19 Treatments and Subsequent Internet Trends: Observational Study.
J Med Internet Res 2020; 22: e20044.
4. Group RC, Horby P, Mafham M, Linsell L, Bell JL, Staplin N, Emberson
JR, Wiselka M, Ustianowski A, Elmahi E, Prudon B, Whitehouse T, Felton
T, Williams J, Faccenda J, Underwood J, Baillie JK, Chappell LC, Faust
SN, Jaki T, Jeffery K, Lim WS, Montgomery A, Rowan K, Tarning J, Watson
JA, White NJ, Juszczak E, Haynes R, Landray MJ. Effect of
Hydroxychloroquine in Hospitalized Patients with Covid-19. N Engl J Med
2020; 383: 2030-40.
5. Axfors C, Schmitt AM, Janiaud P, Van’t Hooft J, Abd-Elsalam S, Abdo
EF, Abella BS, Akram J, Amaravadi RK, Angus DC, Arabi YM, Azhar S, Baden
LR, Baker AW, Belkhir L, Benfield T, Berrevoets MAH, Chen CP, Chen TC,
Cheng SH, Cheng CY, Chung WS, Cohen YZ, Cowan LN, Dalgard O, de Almeida
EVFF, de Lacerda MVG, de Melo GC, Derde L, Dubee V, Elfakir A, Gordon
AC, Hernandez-Cardenas CM, Hills T, Hoepelman AIM, Huang YW, Igau B, Jin
R, Jurado-Camacho F, Khan KS, Kremsner PG, Kreuels B, Kuo CY, Le T, Lin
YC, Lin WP, Lin TH, Lyngbakken MN, McArthur C, McVerry BJ, Meza-Meneses
P, Monteiro WM, Morpeth SC, Mourad A, Mulligan MJ, Murthy S, Naggie S,
Narayanasamy S, Nichol A, Novack LA, O’Brien SM, Okeke NL, Perez L,
Perez-Padilla R, Perrin L, Remigio-Luna A, Rivera-Martinez NE, Rockhold
FW, Rodriguez-Llamazares S, Rolfe R, Rosa R, Rosjo H, Sampaio VS, Seto
TB, Shahzad M, Soliman S, Stout JE, Thirion-Romero I, Troxel AB, Tseng
TY, Turner NA, Ulrich RJ, Walsh SR, Webb SA, Weehuizen JM, Velinova M,
Wong HL, Wrenn R, Zampieri FG, Zhong W, Moher D, Goodman SN, Ioannidis
JPA, Hemkens LG. Mortality outcomes with hydroxychloroquine and
chloroquine in COVID-19 from an international collaborative
meta-analysis of randomized trials. Nat Commun 2021; 12: 2349.
6. Smilkstein MJ, Knapp GL, Kulig KW, Rumack BH. Efficacy of oral
N-acetylcysteine in the treatment of acetaminophen overdose. Analysis of
the national multicenter study (1976 to 1985). N Engl J Med 1988; 319:
1557-62.
7. Brent J. Fomepizole for ethylene glycol and methanol poisoning. N
Engl J Med 2009; 360: 2216-23.
8. Akakpo JY, Ramachandran A, Duan L, Schaich MA, Jaeschke MW,
Freudenthal BD, Ding WX, Rumack BH, Jaeschke H. Delayed Treatment With
4-Methylpyrazole Protects Against Acetaminophen Hepatotoxicity in Mice
by Inhibition of c-Jun n-Terminal Kinase. Toxicol Sci 2019; 170: 57-68.
9. Akakpo JY, Ramachandran A, Kandel SE, Ni HM, Kumer SC, Rumack BH,
Jaeschke H. 4-Methylpyrazole protects against acetaminophen
hepatotoxicity in mice and in primary human hepatocytes. Hum Exp Toxicol
2018; 37: 1310-22.
10. Kang AM, Padilla-Jones A, Fisher ES, Akakpo JY, Jaeschke H, Rumack
BH, Gerkin RD, Curry SC. The Effect of 4-Methylpyrazole on Oxidative
Metabolism of Acetaminophen in Human Volunteers. J Med Toxicol 2020; 16:
169-76.
11. Mullins ME, Yeager LH, Freeman WE. Metabolic and mitochondrial
treatments for severe paracetamol poisoning: a systematic review. Clin
Toxicol (Phila) 2020; 58: 1284-96.
12. Rumack BH, Bateman DN. Acetaminophen and acetylcysteine dose and
duration: past, present and future. Clin Toxicol (Phila) 2012; 50: 91-8.
13. Hendrickson RG. What is the most appropriate dose of
N-acetylcysteine after massive acetaminophen overdose? Clin Toxicol
(Phila) 2019: 1-6.
14. Cairney DG, Beckwith HK, Al-Hourani K, Eddleston M, Bateman DN, Dear
JW. Plasma paracetamol concentration at hospital presentation has a
dose-dependent relationship with liver injury despite prompt treatment
with intravenous acetylcysteine. Clin Toxicol (Phila) 2016; 54: 405-10.
15. Marks DJB, Dargan PI, Archer JRH, Davies CL, Dines AM, Wood DM,
Greene SL. Outcomes from massive paracetamol overdose: a retrospective
observational study. Br J Clin Pharmacol 2017; 83: 1263-72.
16. Chiew AL, Isbister GK, Kirby KA, Page CB, Chan BSH, Buckley NA.
Massive paracetamol overdose: an observational study of the effect of
activated charcoal and increased acetylcysteine dose (ATOM-2). Clin
Toxicol (Phila) 2017; 55: 1055-65.
17. Bateman DN, Dear JW, Thanacoody HK, Thomas SH, Eddleston M,
Sandilands EA, Coyle J, Cooper JG, Rodriguez A, Butcher I, Lewis SC,
Vliegenthart AD, Veiraiah A, Webb DJ, Gray A. Reduction of adverse
effects from intravenous acetylcysteine treatment for paracetamol
poisoning: a randomised controlled trial. Lancet 2014; 383: 697-704.
18. Jacobsen D, Sebastian CS, Barron SK, Carriere EW, McMartin KE.
Effects of 4-methylpyrazole, methanol/ethylene glycol antidote, in
healthy humans. J Emerg Med 1990; 8: 455-61.